Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

V843I, a lung cancer predisposing EGFR mutation, is responsible for resistance to EGFR tyrosine kinase inhibitors.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Sept 2014

Matsushima Satsuki, Ohtsuka Kouki, Ohnishi Hiroaki, Fujiwara Masachika, Nakamura Hiroyuki, Morii Takeshi, Kishino Tomonori, Goto Hajime, Watanabe Takashi

Abstract excerpt

INTRODUCTION: We previously demonstrated that a family predisposed to lung cancer harbored a V843I substitution in the epidermal growth factor receptor (EGFR) protein. We report here the further characterization of this mutant EGFR protein in the context of tumorigenicity and resistance to tyrosine kinase inhibitors (TKIs) of EGFR activity. METHODS: Phosphorylation of EGFR and downstream signaling proteins of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Adenocarcinoma of Lung

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Apoptosis

Share to DNA, Neoplasm

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Flow Cytometry

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 25057940
DOI: 10.1097/JTO.0000000000000241

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

V843I, a lung cancer predisposing EGFR mutation, is responsible for resistance to EGFR tyrosine kinase inhibitors.PMID 25057940Read ↗

EGFR-T790M is a rare lung cancer susceptibility allele with enhanced kinase activity.Semantic proximity Read ↗

Germline EGFR c.2527G > A (p.V843I) variant and familial lung cancer.Semantic proximity Read ↗

EGFR kinase domain mutations - functional impact and relevance for lung cancer therapy.Semantic proximity Read ↗

Clinical and Molecular Characterization of a Rare EGFR cis Compound L833V/H835L Mutation in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Familial lung adenocarcinoma caused by the EGFR V843I germ-line mutation.Semantic proximity Read ↗

Activating ERBB4 mutations in non-small cell lung cancer.Semantic proximity Read ↗

Drug-sensitive FGFR3 mutations in lung adenocarcinoma.Semantic proximity Read ↗

Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer.Semantic proximity Read ↗

Alterations in the Global Proteome and Phosphoproteome in Third Generation EGFR TKI Resistance Reveal Drug Targets to Circumvent ResistanceSemantic proximity Read ↗

Epidermal growth factor receptor as a target enzyme in cancer therapy: Structural and functional insights from crystallography.Semantic proximity Read ↗

An alternative EGFR activation by patient-derived R252C mutation promotes cancer progression.Semantic proximity Read ↗

Good response to gefitinib in a lung adenocarcinoma harboring a heterozygous complex mutation of L833V and H835L in epidermal growth factor receptor gene.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.